Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus ETODOLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus ETODOLAC.
Aspirin vs ETODOLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
325-650 mg PO q4-6h prn; max 4 g/day
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Extended-release: 400-1000 mg orally once daily.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Clinical Note
moderateEtodolac + Gatifloxacin
"Etodolac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateEtodolac + Rosoxacin
"Etodolac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateEtodolac + Levofloxacin
"Etodolac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateEtodolac + Trovafloxacin
"Etodolac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 6.5-7.5 hours (range 5-8 hours). With multiple dosing, the half-life remains unchanged, indicating linear kinetics. No accumulation in normal renal function.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Renal excretion (72% as metabolites, including glucuronides and hydroxylated derivatives, less than 1% unchanged); fecal excretion (16%, primarily as metabolites); biliary excretion contributes to enterohepatic recirculation.
Category C
Category D/X
NSAID / Antiplatelet
NSAID